Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bucking Biosimilar Threat, Roche Sees Further Growth

Executive Summary

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

You may also be interested in...



Roche Ups Outlook, Sees Spark Buy By Year-End

Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.  

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?

Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel